3,053
Views
4
CrossRef citations to date
0
Altmetric
Clinical Features - Review

Type 2 diabetes and cardiovascular disease: risk reduction and early intervention

ORCID Icon, ORCID Icon & ORCID Icon
Pages 2-12 | Received 15 Jun 2022, Accepted 31 Aug 2022, Published online: 18 Oct 2022

Figures & data

Video Abstract

© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

Figure 1. Administration and dose-escalation information for GLP-1RAs with proven CVD benefit [Citation7–9]. CVD, cardiovascular disease; GI, gastrointestinal; GLP-1RA, glucagon-like peptide-1 receptor agonist.

Figure 1. Administration and dose-escalation information for GLP-1RAs with proven CVD benefit [Citation7–9]. CVD, cardiovascular disease; GI, gastrointestinal; GLP-1RA, glucagon-like peptide-1 receptor agonist.

Table 1. Summary of CV risk factor outcomes in GLP-1RA CVOTs.

Table 2. Key data reported in meta-analyses of GLP-1RA CVOTs.

Table 3. Management of common GI AEs associated with GLP-1RAs with proven CV benefit.

Figure 2. Treatment decision-making infographic [Citation4–6].

aIf SGLT2i is not tolerated or contraindicated. ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated hemoglobin; HF, heart failure; OAD, oral antihyperglycemic drug; SGLT2i, sodium-glucose cotransporter-2 inhibitor; T2D, type 2 diabetes.
Figure 2. Treatment decision-making infographic [Citation4–6].
Supplemental material

ipgm_a_2126235_sm0998.mp3

Download MP3 Audio (9.3 MB)

Data availability statement

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.